A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.

Item
http://www.wikidata.org/entity/Q43667872
Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic reviewEscitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
P2860

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.

Item
http://www.wikidata.org/entity/Q43667872
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@en
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@nl
type
label
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@en
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@nl
prefLabel
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@en
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@nl
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
A pharmacoeconomic evaluation ...... tment of depression in Norway.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921